Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ABOS 
Acumen Pharmaceuticals Inc (ABOS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: ABOS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.6
1 Year Target Price $7.6
| 5 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.44% | Avg. Invested days 40 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 79.96M USD | Price to earnings Ratio - | 1Y Target Price 7.6 |
Price to earnings Ratio - | 1Y Target Price 7.6 | ||
Volume (30-day avg) 5 | Beta 0.14 | 52 Weeks Range 0.85 - 3.36 | Updated Date 09/15/2025 |
52 Weeks Range 0.85 - 3.36 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.27 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -39.06% | Return on Equity (TTM) -75.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -33311079 | Price to Sales(TTM) 538.78 |
Enterprise Value -33311079 | Price to Sales(TTM) 538.78 | ||
Enterprise Value to Revenue 89.67 | Enterprise Value to EBITDA -0.6 | Shares Outstanding 60573400 | Shares Floating 32929531 |
Shares Outstanding 60573400 | Shares Floating 32929531 | ||
Percent Insiders 11.46 | Percent Institutions 67.88 |
Upturn AI SWOT
Acumen Pharmaceuticals Inc
Company Overview
History and Background
Acumen Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for Alzheimer's disease. Founded in 1996, the company's initial focus was on neurodegenerative diseases. Acumen shifted its attention to targeting toxic soluble amyloid-beta oligomers (Au03b2Os) and has focused on developing antibodies with potential disease-modifying effects.
Core Business Areas
- Drug Development: Acumen's primary business is the research and development of therapeutic antibodies targeting toxic soluble Au03b2Os for the treatment of Alzheimer's disease.
- Licensing and Partnerships: Acumen may engage in licensing or partnership agreements to advance its drug development programs.
Leadership and Structure
The leadership team consists of Daniel O'Connell, President and Chief Executive Officer. The organizational structure is typical of a biotechnology company, including research, development, clinical operations, and administrative functions.
Top Products and Market Share
Key Offerings
- ACU193: ACU193 is Acumen's lead drug candidate, a humanized IgG1 monoclonal antibody selectively targeting toxic soluble Au03b2Os. It is currently in Phase 1 clinical trials. There is currently no market share data. The market has a wide range of competitors including Biogen (BIIB) with Leqembi, Eli Lilly (LLY) with Donanemab (pending FDA approval) and Roche (RHHBY).
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on Alzheimer's disease is highly competitive. The need for effective treatments is significant due to the aging global population. The industry is characterized by high research and development costs, regulatory hurdles, and the potential for high rewards for successful therapies.
Positioning
Acumen is positioned as a company specializing in targeting toxic soluble Au03b2Os, a specific approach within the broader Alzheimer's disease treatment landscape. Its competitive advantage lies in the selectivity of its antibody for Au03b2Os, potentially leading to fewer side effects than other amyloid-targeting therapies.
Total Addressable Market (TAM)
The global Alzheimer's disease market is estimated to reach hundreds of billions of dollars. Acumen, with its specific approach, could capture a significant portion of this TAM if ACU193 is successful.
Upturn SWOT Analysis
Strengths
- Novel target (Au03b2Os)
- Selective antibody (ACU193)
- Experienced management team
- Strong intellectual property position
Weaknesses
- Early stage clinical development
- High reliance on a single drug candidate (ACU193)
- Limited financial resources compared to larger pharmaceutical companies
- Uncertainty of clinical trial outcomes
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline
- Breakthrough Therapy designation or Fast Track approval from regulatory agencies
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other Alzheimer's disease therapies
- Patent challenges
- Drug pricing pressures
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- RHHBY
Competitive Landscape
Acumen faces competition from established pharmaceutical companies with more resources and late-stage Alzheimer's disease programs. Acumen's advantage lies in its specific target and potential for improved safety.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by the progression of ACU193 through clinical trials.
Future Projections: Future growth depends on the successful development and regulatory approval of ACU193 and other pipeline candidates. Analyst estimates vary widely based on the probability of success.
Recent Initiatives: Focusing on clinical trials for ACU193.
Summary
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical firm concentrating on Alzheimer's disease, specifically targeting toxic soluble amyloid-beta oligomers. Their primary focus is on ACU193, currently in Phase 1 trials, which carries inherent clinical trial risks. The company's success heavily relies on clinical advancement and successful regulatory approval. Investors need to monitor progress carefully, as the future success of Acumen hinges on ACU193's favorable outcome.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data is based on available public information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Acumen Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Newton, MA, United States | ||
IPO Launch date 2021-07-01 | CEO & Director Mr. Daniel J. O'Connell M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 61 | Website https://acumenpharm.com |
Full time employees 61 | Website https://acumenpharm.com | ||
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.